Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ch-PT-8
- Development stage
- Preclinical
- Lead developer
- Kansas City Veteran Affairs Medical Center
- Modality
- Small Molecules
01
Overview
Ch-PT-8 is a preclinical small molecule chalcone derivative designed to target the NLRP3 inflammasome and inhibit reactive oxygen species (ROS) production. Developed by researchers at the Kansas City VA Medical Center, Ch-PT-8 is being investigated for the treatment of epilepsy and neurodegenerative disorders. In preclinical models, the compound has demonstrated significant anti-inflammatory and antioxidant properties, notably suppressing interleukin-1 beta (IL-1β) secretion and reducing both intracellular and mitochondrial ROS levels.
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Ch-PT-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ch-PT-8.